A detailed history of Royal Bank Of Canada transactions in Erasca, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 18,687 shares of ERAS stock, worth $44,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,687
Previous 209,612 91.08%
Holding current value
$44,288
Previous $494,000 89.68%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.17 - $3.28 $414,307 - $626,234
-190,925 Reduced 91.08%
18,687 $51,000
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.63 $371,815 - $546,298
207,718 Added 10967.16%
209,612 $494,000
Q1 2024

Nov 05, 2024

SELL
$1.67 - $2.55 $346,889 - $529,680
-207,718 Reduced 99.1%
1,894 $3,000
Q1 2024

May 15, 2024

SELL
$1.67 - $2.55 $39,116 - $59,728
-23,423 Reduced 92.52%
1,894 $3,000
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $19,652 - $29,302
11,768 Added 86.86%
25,317 $53,000
Q3 2023

Nov 14, 2023

BUY
$1.97 - $2.91 $10,108 - $14,931
5,131 Added 60.95%
13,549 $26,000
Q2 2023

Aug 14, 2023

BUY
$2.57 - $3.3 $11,241 - $14,434
4,374 Added 108.16%
8,418 $23,000
Q1 2023

May 15, 2023

SELL
$2.74 - $4.44 $9,055 - $14,674
-3,305 Reduced 44.97%
4,044 $12,000
Q4 2022

Feb 14, 2023

BUY
$3.89 - $8.57 $25,506 - $56,193
6,557 Added 827.9%
7,349 $31,000
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $2,479 - $4,549
426 Added 116.39%
792 $6,000
Q2 2022

Aug 15, 2022

SELL
$4.58 - $8.72 $146,908 - $279,702
-32,076 Reduced 98.87%
366 $2,000
Q1 2022

May 16, 2022

BUY
$8.6 - $15.48 $241,978 - $435,560
28,137 Added 653.59%
32,442 $279,000
Q4 2021

Feb 14, 2022

BUY
$12.51 - $22.75 $24,857 - $45,204
1,987 Added 85.72%
4,305 $67,000
Q3 2021

Nov 15, 2021

BUY
$17.43 - $24.34 $40,402 - $56,420
2,318 New
2,318 $49,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $289M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.